Eli Lilly’s Q2 Stumble Sparks Market Reaction Despite Strong Earnings
Eli Lilly & Co. (LLY) faced an unexpected market downturn following its Q2 earnings report, despite outperforming analyst expectations. The pharmaceutical giant reported EPS of $6.31, surpassing the $6.07 consensus, while revenue hit $15.56 billion—a 5.83% beat. CEO David Ricks attributed the 38% YoY growth to robust sales of Zepbound and Mounjaro.
The decline stemmed from underwhelming clinical trial data for weight-loss drug orforglipron, which met its primary endpoint but failed to impress investors. The episode highlights the equities market's sensitivity to pipeline developments, even amid strong financials.
Log in to Reply
Log in to comment your thoughtsComments
Related Articles
|Square
Get the BTCC app to start your crypto journey
Get started today Scan to join our 100M+ users